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III: Irreversible: major tissue loss or permanent
nerve damage inevitable if there is significant
delay before intervention. Profound limb
anaesthesia and paralysis. Arterial and venous
Doppler signal inaudible.
Recommendation 48: Urgency of diagnosis of acute
limb ischaemia
Rapid diagnosis of the severity of acute limb
ischaemia and its probable cause is an urgent mat-
ter. Time to diagnosis and successful outcome of
treatment are inversely related.
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C3
OUTCOME ASSESSMENT METHODOLOGY IN
ACUTE LIMB ISCHAEMIA
C 3.1
Introduction
The general approach to the assessment of outcomes
from the diagnosis and treatment of patients with
PAD is outlined in A 3, Outcome Assessment
Methodology in Peripheral Arterial Disease (p 530).
Although the basic methodology remains unchanged
for the evaluation of outcomes in patients treated for
ALI, the primary clinical outcomes criteria differ
because of its more serious nature. The risks and out-
comes in a patient with an acute reduction in distal
blood flow are proportional to the degree of ischaemia
(see Recommendation 47, p 5123). Severity level I is
not dissimilar to chronic CLI, and outcome assessment
of patients with this degree of ischaemia is addressed
in D 3, Outcome Assessment Methodology in Critical
Limb Ischaemia (p 5161).
Patients with more severe levels of acute limb
ischaemia share similar risks and outcomes. Those
who present with levels IIa, lIb, and III ALI have both
an immediate life-threatening and limb-threatening
problem. Patients with class III ischaemia can be sub-
divided into early and late presentations. Those with
early presentations may have some tissue loss from
the forefoot and prolonged nerve dysfunction but may
benefit from an attempt at restoration of distal perfu-
sion. Those with late presentations will require major
amputation because of advanced extensive tissue
ischaemia and necrosis. The risk is not only to limb.
Patients with ALI are also at serious risk of death. The
sudden onset of hypoperfusion of the leg leads rapid-
ly to systemic acid-base and electrolyte disorders that
impair cardiopulmonary function. Elevated myoglo-
bin levels are associated with irreversible renal failure.
Successful revascularisation may induce a severe
reperfusion injury, causing further neuromuscular
damage within the extremity. Thirty-day operative
mortality in recent series has ranged from 9.7% to 17%
1,2,3.4;; but may be as high as 42% in the very elderly,"
The therapeutic goals in these ill patients differ from
those with lesser degrees of circulatory impairment.
The value of any treatment modality must be assessed
accordingly Patient choices and expectations are lim-
ited. Few therapeutic options exist. Invasive interven-
tion, either percutaneous or open, is required.
Therefore, both patient survival and limb preservation
are major priorities in the treatment of the patient with
acute, limb-threatening lower extremity ischaemia.
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These priorities must be reflected in the analysis of the
effectiveness of the care provided to these critically ill
patients.
Recommendation 49: Classification of patients with
severe acute limb ischaemia for outcomes assess-
ment.
Outcomes assessment for patients who present
with acute limb ischaemia of severity level I differs
from those who present with severity levels IIa, lIb,
or III. Therefore, outcomes assessment of the treat-
ment of acute limb ischaemia should be confined to
patients with severity levels IIa, lIb, and III.
Because their limbs are categorically viable, the
outcomes evaluation of patients who present with
severity level I should be assessed separately by
criteria similar to those requiring treatment for
chronic, severe lower extremity ischaemia (see D 3,
P 5161).
C 3.2
Clinical Outcomes
Clinical outcomes are parameters that assess the clini-
cal problem only, such as amputation rate, not those
factors that directly impact on the patient's life, such
as physical functioning and pain. For the treatment of
ALI, major parameters include: technical success of
the treatment; improvements in physical examination,
such as the return of palpable pulses; duplex or anglo-
graphic demonstration of patent arterial anatomy; and
improvement in distal arterial pressures and the
ankle.brachial pressure index (ABPI). The analysis of
periprocedural outcomes in patients with acute,
severe lower extremity ischaemia is complicated by
the fact that baseline parameters are frequently absent.
The clinical urgency of advanced leg ischaemia or
the precarious condition of the patient may prohibit
the acquisition of most baseline clinical information
and mandates expeditious intervention. Fortunately, a
carefully performed physical examination will pro-
vide a significant amount of information. The docu-
mentation of the presence or absence of pulses and
sensory or motor function before treatment establish-
es important clinical parameters with which postoper-
ative assessments can be compared. The restoration of
pulses, a significant improvement in ABPI, and patent
arteries as visualised by duplex imaging or arteriogra-
phy after treatment provide a measure of technical
success.
C 3.2.1
Technical Success
Technical success for the treatment of ALI addresses
the results obtained by any procedure to revascularise
a specific segment of the arterial tree. The technical
success of a procedure used to treat a patient with ALI
is affected by the duration of ischaemia and symptoms
before treatment. In the past, an arbitrary limit of 14
days was often used for the duration of new symp-
toms when assessing the outcome of any treatment for
acute limb ischaemia (see also C 4.4, Results of
Surgical and Endovascular Procedures for Acute Limb
Ischaemia, p 5132).
During a clinical procedure, it may seem desirable
to track the impact of each technical component.
Although the removal of clot would seem easy to doc-
ument, the specific technical success of an intervention
may be difficult to evaluate. The extraction of thrombi
from the major vessels of the lower extremity does not
guarantee distal reperfusion. This is because of the
possibility of the extension of thrombus into, or shut-
down by spasm, oedema, or thrombosis, of the sm all
nutrient vessels that are not visualised by arteriogra-
phy. Additionally, the complete removal of clot may
reveal a significant underlying occlusive lesion or may
be marked by the appearance of a clinically significant
reperfusion injury.
Recommendation 50: Assessment of technical success
in relation to duration of acute limb ischaemia
Assessment of technical success of a procedure used
for the treatment of patients with acute limb
ischaemia of severity levels IIa, lIb, or early III should
be limited to the results obtained with patients who
have had symptoms for a short duration, which
should be dearly stated in the publication.
Recommendation 51: Assessment of technical sue-
cess of multiple interventions
When treatment involves multiple modalities, such
as thrombolytic therapy and open surgery, "techni-
cal success" should be reported as overall technical
success during the same hospitalisation period
rather than the success of each component of thera-
py, although the success of each component of ther-
apy also should be reported.
C 3.2.2
Anatomic and Haemodynamlc Improvement
All patients with ALI should have at least a detailed
physical examination documenting the condition of
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the affected leg. This includes the assessment of capil-
lary filling, sensory and motor function, the presence
or absence of pulses, and Doppler arterial studies.
Preoperative duplex imaging or angiography are
desirable, but only when the patient's condition per-
mits. The ABPI is rarely measurable at the time of
presentation and in the acute setting tends to improve
steadily after intervention. For these reasons, ABPI
change is less useful in the assessment of treatment
success in acute as opposed to chronic critical limb
ischaemia. However, successful revascularisation
should lead to a measurable ABPI above the "critical
range" of 40 to 60 mm Hg. All patients should there-
fore have postoperative ABPI recorded and appropri-
ate imaging of the treated arterial segment to docu-
ment the anatomic and haemodynamic status. It may
be necessary and appropriate to use toe pressures or
evaluation of pulse volume recordings to determine
postprocedural haernodynamic status.
Recommendation 52: Haemodynamic status in
acute limb ischaemia
Patients who have undergone attempted revascu-
larisation should have postoperative ankle or toe
pressure measurements and appropriate imaging of
the treated arterial segment in all cases.
C 3.2.3
Effectiveness Assessment
The effectiveness of a procedure is an overall measure
of the impact of an intervention on a patient's life. To
accomplish this, physicians need to understand not
only the usual clinical criteria of success but also the
long-term or serious complications associated with a
given therapeutic modality. Also, understanding how
the underlying condition affects a patient's life permits
the estimation of the perceived benefit of a treatment.
Procedural mortalitu and morbidity
Short-term procedural morbidity refers to those com-
plications of treatment that are of significant magni-
tude to prolong hospitalisation or require specific
therapy but do not indefinitely alter the patient's life.
The acute morbidity of treatment is related to the
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severity of ischaemia and the therapeutic modality
employed. Overall, procedural complications are com-
mon, occurring in more than 50% of patientsp,s.9
Acute, limb-threatening ischaemia has a significant
mortality both because of the underlying diseases that
induce or are associated with it and because of the
metabolic derangement that occurs as a result of the
acute insult.
-jivegard et al lO identified five admission criteria,
each of which will significantly predict a high risk of
cardiac death: mean arterial pressure of less than 90
mm Hg, clinical signs of cardiac failure, ischaemia
extending to the thigh, a haemoglobin level over 14
g/dL, and a history of myocardial infarction in the
previous 4 weeks.
The sudden interruption of flow to the leg may be
caused by either thrombosis or embolism. Emboli
may be from cardiac or proximal arterial sources.
Atrial fibrillation is the most common source of
emboli. Typically, patients with ALI are elderly.
Thus, preexisting cardiac or cerebral problems are
common in patients presenting with acute hypoper-
fusion of the leg. Myocardial infarction or fatal
arrhythmia account for most of the deaths in this
group of patients. Despite advances in revascularisa-
tion and cardiac support, the mortality of ALI
remains high (10% to 20%) and even higher in elder-
ly subjects.1•2•3.4,S.6
As with the treatment of all forms of disease, long-
term procedural complications include not only
those inflicting permanent disabilities but all those
that negatively alter or significantly delay the
patient's progress toward improvement. For the
assessment of effectiveness of therapy, complica-
tions that yield serious or long-term morbidity must
be evaluated and weighed against the benefit
achieved. Although the most obvious source of long-
term morbidity may be limb loss, a more significant
complication resulting from the treatment of ALI
may be renal failure from myoglobinuria.
Myoglobin is a direct renal toxin, so the resultant
renal failure may be severe and prolonged, requiring
the patient to be placed on haemodialysis. As an
independent procedure, haemodialysis is associated
with a yearly mortality of nearly 10%11
Limb loss represents treatment failure for patients
with severity levels IIa and Ilb acute limb ischaemia.
This may be attributable to the inability to extract
sufficient clot or to treat all of the offending occlu-
sive disease or to a delay in therapy resulting in dif-
fuse myonecrosis. Limb loss is associated with a sig-
nificant and permanent alteration in patient lifestyle
and often requires prolonged rehabilitation (see also
Amputation, D 4.17, P 5225).
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Recurrence of symptoms
Acute limb ischaemia associated with embolisation
has a significant incidence of recurrence. Recurrent
ischaemia caused by embolisation ma y be experienced
by as many as 43% of patients in the absence of anti-
coagulation.P Each episode reduces the likelihood of
complete restoration of blood flow into the leg and
fool. In addition, the sites of recurrent embolisation
may vary and may include arch or visceral vessels
leading to patient death,13·H Ischaemia from thrombo-
sis is also associated with a high incidence of recur-
rence .1S.16Acute thrombosis generally occurs in the set-
ting of atherosclerosis, so acute arterial reocclusion is
common if no additional intervention for the treat-
ment of the underlying occlusive lesions is undertak-
en. This is well documented for both thrombolytic
therapy and for open thromboembolectomy. In the
former, the incidence of recurrent ischaemia may be as
high as 53%,17,18whereas the latter may be associated
with an incidence of reocclusion of 21% to 26%.19,20
Health-related quality of life
As defined in A 3.2.8, Valuing Health-Related Quality
of Life and Utility Assessment, assessment of health-
related quality of life attempts to identify the general
well-being of a patient through evaluation of overall
functional status, perceived health, psychological
well-being, and role function. Currently, this is most
easily accomplished by use of the 5F-36 assessment
tool. Although patients with ALI of severity levels IIa,
lIb, or III may not be able to complete this question-
naire before intervention, the assessment tool may
provide insight into the status of the patient during
recovery (see Recommendation 3, p 536).
Recommendation 53: Assessment of quality of life
after treatment of acute limb ischaemia.
A validated quality-of-life questionnaire is recom-
mended to measure generic health status after treat-
ment in patients with acute limb ischaemia of
severity levels IIa, lIb, or early III.
Functional status
The functional status of the patient posttreatment can
be evaluated through the use of a disease-specific
questionnaire and correlated with walking distance if
there are no residual foot lesions, nerve deficits, or
muscle fibrosis. Often there is insufficient time to eval-
uate functional status before treatment because of the
need to proceed to intervention. However posttreat-
ment evaluation is still useful even if baseline values
have not been obtained and particularly when com-
paring two treatments or when a patient was original-
ly asymptomatic. The Walking Impairment
Questionnaire (WIQ) had been designed to evaluate
the impact of mild to moderate limb ischaemia on leg
function. There are no currently available disease-spe-
cific instruments directed toward the evaluation of
patients with acute limb ischaemia, and currently the
WIQ may be the best option (see Recommendation 2,
p 534, and Critical Issue 2, p 534).
Recommendation 54: Parameters for reporting the
success of treatment for acute limb ischaemia.
In determining the success of a treatment procedure
for acute limb ischaemia of severity levels IIa, lIb,
or early III, the following outcomes should be doc-
umented:
1. Objective outcome: Event-free survival, limb sal-
vage, tissue salvage, neurological status of the
limb, renal status, procedural" morbidity, preser-
vation of function of the intact and healed target
limb as measured by standardised reporting cri-
teria, including technical success, haernodynam-
ic status, and claudication distance, however
measured.
2. Symptomatic outcome: Limb pain and function.
3. General quality of life: A return over time of the
attributes to a pre-acute state or to the level
reported by those patients with similar cornor-
bidities (eg, as measured by the SF-36 question-
naire).
4. Postrevascularisation: Limb retention and func-
tion, the need for additional therapies, and proof
of patency of the revascularised segment (see A
3.2.9).
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C4
TREATMENT FOR ACUTE LIMB ISCHAEMIA
Acute arterial occlusion can be associated with a spec-
trum of presenting signs and symptoms (see
Differential Diagnosis, C 2.1.3, P 5117). At one
extreme, a patient without underlying arterial occlu-
sive disease who suffers an acute embolic occlusion at
the femoral bifurcation may present with a profound-
ly ischaemic lower extremity, necessitating urgent
intervention. In contrast, at the other extreme, an acute
embolic or thrombotic occlusion of a chronically dis-
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eased but only partially patent artery may be associat-
ed with only mild progression of chronic symptoms
and modest deterioration in haemodynamics. The
problems presented by the acutely ischaemic limb are
compounded by inadequate opportunities to treat sig-
nificant comorbidities and by the problems after
revascularisation caused by reperfusion injury.
Therefore, the acutely ischaemic limb can present an
extreme clinical challenge to the clinician. Despite
progress in many areas of vascular reconstruction, ALI
continues to be associated with substantial limb loss
and appreciable mortality, usually attributable to
coexistent cardiac disease (10%-20%).1-2·3.4
C 4.1
Immediate Management of Acute Limb Ischaemia
The treatment of ALI is an emergency situation.
Minimising any delay in relieving the occlusion is
essential, because risk of limb loss increases with the
duration of the acute ischaemia. In one study, the
amputation rates were found to be proportional to the
interval between onset of acute limb ischaemia and
exploration (6% if within 12 hours, 12% within 13 to 24
hours, and 20% after 24 hours). Most older studies
show even higher amputation rates with time. It is
therefore important to eliminate diagnostic measures
that are not essential to the needed intervention and to
immediately make preliminary arrangements for that
treatment, insisting on its priority.
Pre-intervention anticoagulation with therapeutic
levels of heparin reduces morbidity and mortality
(compared with not using anticoagulants) and is part
of the overall treatment strategy for these patientsP It
not only helps prevent clot propagation but, in the
case of arterial embolism, mitigates against another
embolus. Therefore, the immediate emergency man-
agement of all such patients includes heparinisation.
Administration of heparin may be briefly delayed in
cases in which spinal or epidural anaesthesia is impor-
tant for overall patient management. Pain should be
controlled by appropriate analgesia. Oxygen inhala-
tion may be helpful, and there is some experimental
evidence of its benefit," Appropriate treatment for con-
gestive cardiac failure or atrial or ventricular arrhyth-
mias should be initiated. These and other such sup-
portive measures should be commenced immediately
and continued through the intervention, rather than
waiting until after it. Their ultimate importance can-
not be overemphasised.
There is no evidence that vasoactive drugs are help-
ful in ALI. The same can be said for sympathectomy.
Wherever possible, simple measures to improve exist-
